272770-45-3

Upstream product

• 61049-69-2 3-O-benzylmaltol 
• 272770-44-2 tert-butyl 2,6-di-tert-butyl-4-(18-amino-4,7,10,13,16-pentaoxaoctadecyl)phenyl carbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 272770-42-0 methanesulfonic acid 2-{2-[2-(2-{2-[3-(4-tert-butoxycarbonyloxy-3,5-di-tert-butyl-phenyl)-propoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethyl ester 
• 272770-43-1 carbonic acid 4-{3-[2-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propyl}-2,6-di-tert-butyl-phenyl ester tert-butyl ester 
• 272770-41-9 carbonic acid tert-butyl ester 2,6-di-tert-butyl-4-{3-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propyl}-phenyl ester 
• 4792-15-8 Pentaethylene glycol 
• 272770-34-0 carbonic acid tert-butyl ester 2,6-di-tert-butyl-4-(3-iodo-propyl)-phenyl ester 
• 224564-43-6 4-(3-Iodopropyl)-2, 6-di-tert-butylphenol 

Downstream Products

• 272770-46-4 tert-butyl 4-(18-(1,4-dihydro-3-hydroxy-2-methyl-4-oxo-1-pyridinyl)-4,7,10,13,16-pentaoxaoctadecyl)-2,6-di-tert-butylphenyl carbonate 

Relevant academic research and scientific papers

Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.

Water soluble prodrugs of hybrid free radical scavenger/iron chelating molecules, based on 3,5-disubstituted-4-hydroxyphenyl derivatives and 3-hydroxy-2-methyl-4(1H)-pyridinone (deferiprone), have been prepared. Related hybrid molecules containing a covalent poly(ethylene)glycol or an amine linker were also synthesized.

3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers

A compound of the formula (1): wherein A is wherein R1, R2and R3are independently selected from H and alkyl; wherein X is O, S, NR4or a direct bond, wherein R4is H or alkyl; wherein Z is a saturated hydrocarbyl chain comprising from 1 to 20 carbon atoms interrupted by one or more heteroatom(s) and optionally substituted by one or more oxo substituent(s); wherein q is 1, 2 or 3; wherein if q is 2 or 3, then each A can be the same or different; wherein the or each R5is independently selected from H and alkyl; wherein the or each R6is independently selected from alkyl; wherein n is 1 to 5; wherein p is 0 to 4; and wherein the sum of n and p is less than 6, or a pharmaceutically acceptable salt thereof, and the use thereof in therapy, particularly for the treatment of a condition associated with oxidative stress, such as oxidative damage of the central nervous system or an acute or chronic neurological disorder such as traumatic brain injury, spinal cord injury, cerebral tumour, subharrachnoid haemorrage/cerebral vasospasm, cerebral ischaemia, stroke (ischaemic or haemorragic), Alzheimer's disease, Huntington's Disease, Parkinson's Disease, Friedrich's ataxia, motor neuron disease or multiple sclerosis.